Cargando…

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial

INTRODUCTION: Increasing the frequency of blood glucose monitoring aids the evaluation of glycemic variability and blood glucose control by antidiabetic drugs. It remains unclear, however, whether GLP-1 receptor agonists or basal insulin has a better effect on glycemic variability in type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Ting-Ting, Bi, Yan, Li, Ping, Shen, Shan-Mei, Xiong, Xiao-Lu, Gao, Li-Jun, Jiang, Can, Wang, Yan, Feng, Wen-Huan, Zhu, Da-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984915/ https://www.ncbi.nlm.nih.gov/pubmed/29744819 http://dx.doi.org/10.1007/s13300-018-0412-6

Ejemplares similares

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial
por: Yin, Ting-Ting, et al.
Publicado: (2018)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yang, Yunjiao, et al.
Publicado: (2022)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
por: Secnik Boye, Kristina, et al.
Publicado: (2006)

Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
por: Li, Yan, et al.
Publicado: (2019)

Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
por: Luo, Menghui, et al.
Publicado: (2020)

Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD
por: Liu, Lin, et al.
Publicado: (2023)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Effect of the Chinese New Year Public Holiday on the Glycemic Control of T1DM With Intensive Insulin Therapy
por: Guo, Keyu, et al.
Publicado: (2022)

Paeoniflorin ameliorates glycemic variability-induced oxidative stress and platelet activation in HUVECs and DM rats
por: Huang, Ye, et al.
Publicado: (2020)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes
por: Pistrosch, F., et al.
Publicado: (2013)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
por: Elhabashy, Safinaz Adel, et al.
Publicado: (2023)

Corrigendum: Effect of the Chinese New Year public holiday on the glycemic control of T1DM with intensive insulin therapy
por: Guo, Keyu, et al.
Publicado: (2022)

Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study
por: del Olmo-García, Maria Isabel, et al.
Publicado: (2020)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus
por: Akyay, Ozlem Zeynep, et al.
Publicado: (2023)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
por: Shafie, Asrul Akmal, et al.
Publicado: (2020)

Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
por: Ling, James, et al.
Publicado: (2021)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease
por: LI, JILING, et al.
Publicado: (2014)

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
por: Chen, Weena J. Y., et al.
Publicado: (2017)

Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
por: Krämer, Anna L., et al.
Publicado: (2020)

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022)

Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
por: White, Neil H., et al.
Publicado: (2009)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013)

Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice
por: Li, Yanli, et al.
Publicado: (2018)

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial
por: Bunck, Mathijs C., et al.
Publicado: (2009)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus(®)): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
por: Yan, Xiang, et al.
Publicado: (2022)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open‐label, controlled trial
por: Feng, Wenhuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2b85884ud470r3iv2j5aiqrovo